RE:RE:RE:Last Patient enrolled recovers in 10 days, great newsOn Nov. 30, Algernon is pleased to announce that the final patient has been enrolled in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.
Dec. 24, 2020 Algernon is pleased to announce that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, has now completed treatment as well as the required two-week follow up.
I made the assumption that it is the same last patient. If you have 2 weeks of follow up, that means the person was released from the hospital on Dec 10th
I also believe that adding additional patients to the trial had nothing to do with attrition, the CRO saw a signal and in order to see statistical significant, they advised Algernon to add more patients on the treatment arm, this is my interpretation